INmune Bio enters services agreement with Uniphar for Ebstrocel commercialization

INMB•2026-10-21

INmune Bio entered a master services agreement with Uniphar for Ebstrocel international commercialization and plans to pursue named-patient access in Europe and MENA.

1. Commercialization agreement

INmune Bio entered a master services agreement with Uniphar for Ebstrocel international commercialization. The company plans to pursue named-patient access for Ebstrocel in Europe and MENA.

INmune Bio enters services agreement with Uniphar for Ebstrocel commercialization

1. Commercialization agreement

Related News

Trinity Capital Inc: Clear Street raises target price to $19 from $18

Fastenal Company: Argus Research raises target price to $59 from $55

Runway Growth Finance raised to buy from hold; target price cut to $7.5 from $10

Cerenome’s REYOBIQ combination extends survival in ovarian cancer mouse models

Deutsche Telekom, Nokia and NVIDIA achieve 10-15% uplink throughput gains in AI-RAN lab tests